
|Articles|December 10, 2013
New Therapies in Development for Multiple Myeloma
Author(s)Joseph R. Mikhael, MD
In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.
Advertisement
Joseph R. Mikhael, MD, of the Mayo Clinic in Arizona, discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development for multiple myeloma, both for treatment-naive and relapsed refractory patients, including the next-generation novel proteasome inhibitors, ixazomib (MLN9708) and oprozomib. Dr. Mikhael also highlights several monoclonal antibodies.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Drug Class is Convenient and Meaningful in Multiple Myeloma Landscape
2
Zongertinib Yields Enduring Activity in Frontline HER2+ NSCLC Trial
3
Dose Modification Strategies in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
4
Utilizing AI Algorithms to Inform Breast Cancer Chemoprevention Strategies
5


























































